AnaptysBio, Inc.

ANAB • Biotechnology

$56.80

▼ -0.66 (-1.15%)

Current price

EarningsLatest report: Mar 31, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$1.63B

Growth

4.6%

Cash Flow

1/5

Trend

Volatile

Evidence

Stable or improving margins · -5.6%Positive revenue growth · 38.4%Positive free cash flow · 0.71Manageable debt level · 0.38Healthy liquidity · 9.07

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Sep 4, 2026, 12:10 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$56.80

Change-1.15%

Shares Out28.69M

Market Cap$1.63B

Enterprise Value$1.61B

52W Range11.40 - 72.36

Beta0.40

P/E-60.84

P/S7.01

P/B127.85

P/FCF369.62

EV/Sales6.92

Price$56.80

Change-1.15%

Shares Out28.69M

Market Cap$1.63B

Enterprise Value$1.61B

52W Range11.40 - 72.36

Beta0.40

P/E-60.84

P/S7.01

P/B127.85

P/FCF369.62

EV/Sales6.92

EV/EBITDA30.17

EV/FCF364.95

Earnings Yield-1.64%

FCF Yield0.27%

Dividend Yield0.00%

Gross Margin98.97%

Oper. Margin20.42%

Profit Margin-5.64%

Debt/Eq0.38

Current Ratio9.07

Quick Ratio9.07

Revenue 5Y4.59%

Target$73.17

Target Upside28.82%

Target Median$75.50

Target Range50.00 - 90.00

Volume363.81K

Avg Volume592.56K

EPS Surprise-1.52

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

43/100

Financial Strength

Debt, cash, stability

75/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

46/100

Why this score▼

Stable or improving margins · -5.6%Positive revenue growth · 38.4%Positive free cash flow · 0.71Manageable debt level · 0.38Healthy liquidity · 9.07

Analyst view

Analyst sentiment and price target

ANAB

Analyst sentiment

Based on 23 analyst votes · 2026-09-05

87/100

Bullish

Hold

Bearish

Price Target

2026-09-04

Low

$50.00

Mean

$74.86

Median

$76.00

High

$90.00

Company Overview

IPO: 1/26/2017

Industry: Biotechnology

P/B i: 127.85

Debt / Equity i: 0.38

Operating Margin: 20.42%

Net Margin: -5.64%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.38

Current Ratio: 9.07

Quick Ratio: 9.07

Status: Good

Insider Transactions

Recent executive and insider activity

Faga Daniel

Transaction: 03/12/2026

BUY

Change

+53,334

Price

Not reported

Filing

08/07/2026

Type

BUY

Lizzul Paul F.

Transaction: 03/12/2026

BUY

Change

+16,667

Price

Not reported

Filing

08/07/2026

Type

BUY

Orwin John A

Transaction: 06/15/2026

SELL

Change

-6,030

Price

Not reported

Filing

06/17/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Faga Daniel	BUY	+53,334	Not reported	03/12/2026	08/07/2026
Lizzul Paul F.	BUY	+16,667	Not reported	03/12/2026	08/07/2026
Orwin John A	SELL	-6,030	Not reported	06/15/2026	06/17/2026
Orwin John A	BUY	+6,030	Not reported	06/15/2026	06/17/2026
RENTON HOLLINGS	SELL	-6,030	Not reported	06/15/2026	06/17/2026
RENTON HOLLINGS	BUY	+6,030	Not reported	06/15/2026	06/17/2026
Schmid John P.	SELL	-6,030	Not reported	06/15/2026	06/17/2026
Schmid John P.	BUY	+6,030	Not reported	06/15/2026	06/17/2026
Murphy Christopher M.	OTHER	0	Not reported	05/11/2026	05/13/2026
Murphy Christopher M.	BUY	+25,765	Not reported	05/11/2026	05/13/2026
Hughes Owen	OTHER	0	Not reported	05/11/2026	05/13/2026
Hughes Owen	BUY	+11,250	Not reported	05/11/2026	05/13/2026
GRAY SUSANNAH	BUY	+11,250	Not reported	04/27/2026	04/29/2026
Faga Daniel	SELL	-11,000	$31.12	04/20/2026	04/23/2026
Faga Daniel	SELL	-2,321	$31.12	04/20/2026	04/22/2026
RENTON HOLLINGS	BUY	+5,500	$32.17	04/20/2026	04/22/2026
Schmid John P.	BUY	+5,500	$32.17	04/20/2026	04/22/2026
Orwin John A	BUY	+3,311	$14.29	04/20/2026	04/22/2026
GRAY SUSANNAH	OTHER	0	Not reported	03/26/2026	04/03/2026
Schmid John P.	SELL	-522	$57.40	03/30/2026	04/01/2026

About the Company

AnaptysBio, Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Source - link

Peers

BBOT DNTH KOD MNMD NRIX OCS PHAT TSHA URGN XNCR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

GlobeNewsWire

16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned

Defense World

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

Zacks Investment Research

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.

Seeking Alpha

AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy?

AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 753,749 shares. The stock had previously closed at $54.15. Analysts Set

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-12	-0.32	-1.84	-1.52
2026-03-03	0.89	1.58	0.69
2025-11-04	-1.06	0.52	1.58
2025-08-07	-1.5	-1.34	0.16
2025-05-05	-1.3	-1.28	0.02
2025-02-27	-1.55	-0.72	0.83
2024-11-05	-1.72	-1.14	0.58
2024-08-05	-1.2	-1.71	-0.51
2024-05-09	-1.54	-1.64	-0.1
2024-03-12	-1.60067	-1.59	0.01067
2023-11-02	-1.72	-1.41	0.31
2023-08-07	-1.6954	-1.5	0.1954